Abstract:Background: Renal cell carcinoma (RCC) is the most prevalent type of malignant kidney tumor in adults, with clear cell renal cell carcinoma (ccRCC) comprising about 75% of all cases. The SETD2 gene, which is involved in the modification of histone proteins, is often found to have alterations in ccRCC. Yet, our understanding of how these SETD2 mutations affect ccRCC characteristics and behavior within the tumor microenvironment is still not fully understood. Methods: We conducted a detailed analysis of single-cell RNA sequencing (scRNA-seq) data from ccRCC. First, the data was preprocessed using the Python package, "scanpy." High variability genes were pinpointed through Pearson's correlation coefficient. Dimensionality reduction and clustering identification were performed using Principal Component Analysis (PCA) and the Leiden algorithm. Malignant cell identification was conducted with the "InferCNV" R package, while cell trajectories and intercellular communication were depicted using the Python packages "VIA" and "cellphoneDB." We then employed the R package "Deseq2" to determine differentially expressed genes (DEGs) between groups. Using high-dimensional weighted gene correlation network analysis (hdWGCNA), co-expression modules were identified. We intersected these modules with DEGs to establish prognostic models through univariate Cox and the least absolute shrinkage and selection operator (LASSO) method. Results: We identified 69 and 53 distinctive cell clusters, respectively. These were classified further into 12 unique cell types. This analysis highlighted the presence of an abnormal tumor sub-cluster (MT + group), identified by high mitochondrial-encoded protein gene expression and an indication of unfavorable prognosis. Investigation of cellular interactions spotlighted significant interactions between the MT + group and endothelial cells, macrophaes. In addition, we developed a prognostic model based on six characteristic genes. Notably, risk scores derived from these genes correlated significantly with various clinical features. Finally, a nomogram model was established to facilitate more accurate outcome prediction, incorporating four independent risk factors. Conclusion: Our findings provide insight into the crucial transcriptomic characteristics of ccRCC associated with SETD2 mutation. We discovered that this mutation-induced subcluster could stimulate M2 polarization in macrophages, suggesting a heightened propensity for metastasis. Moreover, our prognostic model demonstrated effectiveness in forecasting overall survival for ccRCC patients, thus presenting a valuable clinical tool.

SETD2 deficiency impairs β-catenin destruction complex to facilitate renal cell carcinoma formation

Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma

Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.

SETD2 Deficiency Accelerates Sphingomyelin Accumulation and Promotes the Development of Renal Cancer.

Figure S4 from Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma

Setd2, A H3k36 Lysine Methyltransferase, is Essential for Adult Normal Hematopoiesis and Leukemia Stem Cells

SETD7 Promotes Cell Proliferation and Migration Via Methylation-mediated TAF7 in Clear Cell Renal Cell Carcinoma

Revealing the characteristics of SETD2-mutated clear cell renal cell carcinoma through tumor heterogeneity analysis

Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients with Nonmetastatic Clear-Cell Renal Cell Carcinoma.

Loss of SETD2‐mediated Downregulation of Intracellular and Exosomal Mirna‐10b Determines MAPK Pathway Activation and Multidrug Resistance in Renal Cancer

Abstract 7074: Perturbed RNA N6-methyladenosine methylome in SETD2 mutant clear cell renal carcinoma

Deficiency of Histone H3K36 Methyltransferase SETD2 Inhibits Proliferation and Migration of Hepatocellular Carcinoma Through ERK Pathway

Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis

SETD2 Deficiency Promotes Renal Fibrosis Through the TGF‐β/Smad Signalling Pathway in the Absence of VHL

SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways

Histone Methyltransferase SETD2 Modulates Alternative Splicing to Inhibit Intestinal Tumorigenesis.

Tables S2 from Multilevel Regulation of Β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma

Loss of MLH1 Confers Resistance to PI3Kβ Inhibitors in Renal Clear Cell Carcinoma with SETD2 Mutation

Histone Methyltransferase SETD2: a Potential Tumor Suppressor in Solid Cancers

Deficiency of Histone Methyltransferase SET Domain-Containing 2 in Liver Leads to Abnormal Lipid Metabolism and HCC.

Loss of SETD2 Aggravates Colorectal Cancer Progression Caused by SMAD4 Deletion Through the RAS/ERK Signalling Pathway.